Baseline serum C-reactive protein and death from colorectal cancer in the NHANES III cohort

International Journal of Cancer

Volumn 134, Issue 8, 2014, Pages 1862-1870

  Swede, Helen ^a   Hajduk, Alexandra M ^b   Sharma, Jyoti ^c   Rawal, Shristi ^a   Rasool, Homaira ^a   Vella, Anthony T ^a   Tobet, Rebecca E ^a   Stevens, Richard G ^a  

^a UNIVERSITY OF CONNECTICUT HEALTH CENTER   (United States)

^b UNIVERSITY OF MASSACHUSETTS MEDICAL SCHOOL   (United States)

^c WESTCHESTER MEDICAL CENTER   (United States)

Author keywords

anti inflammatory drugs; body mass index; C reactive protein; cancer; central adiposity; colon cancer; colorectal cancer; inflammation; neoplasms; obesity

Indexed keywords

ANTI-INFLAMMATORY DRUGS; BODY MASS INDEX; C-REACTIVE PROTEIN; CANCER; CENTRAL ADIPOSITY; COLON CANCER; COLORECTAL CANCER; INFLAMMATION; NEOPLASMS; OBESITY;

AGED; AGED, 80 AND OVER; BODY WEIGHT; C-REACTIVE PROTEIN; CARDIOVASCULAR DISEASES; COHORT STUDIES; COLORECTAL NEOPLASMS; CROSS-SECTIONAL STUDIES; FEMALE; HUMANS; INFLAMMATION; MALE; MIDDLE AGED; NUTRITION SURVEYS; OBESITY; PROSPECTIVE STUDIES; TREATMENT OUTCOME; TUMOR MARKERS, BIOLOGICAL; WAIST CIRCUMFERENCE;

EID: 84893799609     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.28504     Document Type: Article

References (50)

1. Roberts DL, Dive C, Renehan AG,. Biological mechanisms linking obesity and cancer risk: new perspectives. Annu Rev Med 2010; 61: 301-16.
2. Calabro P, Limongelli G, Pacileo G, et al. The role of adiposity as a determinant of an inflammatory milieu. J Cardiovasc Med 2008; 9: 450-60. (Pubitemid 351521626)
3. Kim K, Valentine RJ, Shin Y, et al. Associations of visceral adiposity and exercise participation with C-reactive protein, insulin resistance, and endothelial dysfunction in Korean healthy adults. Metabolism 2008; 57: 1181-9.
4. Khaodhiar L, Ling P-R, Blackburn GL, et al. Serum levels of interleukin-6 and C-reactive protein correlate with body mass index across the broad range of obesity. J Parenter Enteral Nutr 2004; 28: 410-15. (Pubitemid 39463824)
5. Heikkilä K, Ebrahim S, Lawlor DA,. A systematic review of the association between circulating concentrations of C reactive protein and cancer. J Epidemiol Community Health 2007; 61: 824-33.
6. Peisajovich A, Marnell L, Mold C, et al. C-reactive protein at the interface between innate immunity and inflammation. Expert Rev Clin Immunol 2008; 4: 379-90. (Pubitemid 351903275)
7. Terzic J, Grivennikov S, Karin E, et al. Inflammation and colon cancer. Gastroenterology 2010; 138: 2101-2114.e5.
8. Gunter MJ, Stolzenberg-Solomon R, Cross AJ, et al. A prospective study of serum C-reactive protein and colorectal cancer risk in men. Cancer Res 2006; 66: 2483-7.
9. Tsilidis KK, Branchini C, Guallar E, et al. C-reactive protein and colorectal cancer risk: a systematic review of prospective studies. Int J Cancer 2008; 123: 1133-40.
10. Balkwill F, Mantovani A,. Inflammation and cancer: back to Virchow? Lancet 2001; 357: 539-45. (Pubitemid 32173595)
11. Erlinger TP, Platz EA, Rifai N, et al. C-reactive protein and the risk of incident colorectal cancer. JAMA 2004; 291: 585-90. (Pubitemid 38500312)
12. Il'yasova D, Colbert LH, Harris TB, et al. Circulating levels of inflammatory markers and cancer risk in the health aging and body composition cohort. Cancer Epidemiol Biomarkers Prev 2005; 14: 2413-18. (Pubitemid 41437845)
13. Trichopoulos D, Psaltopoulou T, Orfanos P, et al. Plasma C-reactive protein and risk of cancer: a prospective study from Greece. Cancer Epidemiol Biomarkers Prev 2006; 15: 381-4. (Pubitemid 43348407)
14. Siemes C, Visser LE, Coebergh JW, et al. C-reactive protein levels, variation in the C-reactive protein gene, and cancer risk: the Rotterdam Study. J Clin Oncol 2006; 24: 5216-22. (Pubitemid 46631365)
15. Ito Y, Suzuki K, Tamakoshi K, et al. Colorectal cancer and serum C-reactive protein levels: a case-control study nested in the JACC Study. J Epidemiol 2005; 15 (Suppl 2): S185-S189. (Pubitemid 41410102)
16. Otani T, Iwasaki M, Sasazuki S, et al.; Japan Public Health Center-Based Prospective Study G. Plasma C-reactive protein and risk of colorectal cancer in a nested case-control study: Japan Public Health Center-based prospective study. Cancer Epidemiol Biomarkers Prev 2006; 15: 690-5.
17. Zhang SM, Buring JE, Lee IM, et al. C-reactive protein levels are not associated with increased risk for colorectal cancer in women. Ann Intern Med 2005; 142: 425-32.
18. Aleksandrova K, Jenab M, Boeing H, et al. Circulating C-reactive protein concentrations and risks of colon and rectal cancer: a nested case-control study within the European Prospective Investigation into Cancer and Nutrition. Am J Epidemiol 2010; 172: 407-18.
19. Heikkila K, Harris R, Lowe G, et al. Associations of circulating C-reactive protein and interleukin-6 with cancer risk: findings from two prospective cohorts and a meta-analysis. Cancer Causes Control 2009; 20: 15-26.
20. Toriola AT, Cheng TY, Neuhouser ML, et al. Biomarkers of inflammation are associated with colorectal cancer risk in women but are not suitable as early detection markers. Int J Cancer 2013; 132: 2648-58.
21. Yudkin JS, Stehouwer CD, Emeis JJ, et al. C-reactive protein in healthy subjects: associations with obesity, insulin resistance, and endothelial dysfunction: a potential role for cytokines originating from adipose tissue. Arterioscler Thromb Vasc Biol 1999; 19: 972-8. (Pubitemid 29177345)
22. Gunter MJ, Leitzmann MF,. Obesity and colorectal cancer: epidemiology, mechanisms and candidate genes. J Nutr Biochem 2006; 17: 145-56. (Pubitemid 43247408)
23. Fogarty AW, Glancy C, Jones S, et al. A prospective study of weight change and systemic inflammation over 9 y. Am J Clin Nutr 2008; 87: 30-5.
24. Park HS, Park JY, Yu R,. Relationship of obesity and visceral adiposity with serum concentrations of CRP, TNF-α and IL-6. Diabetes Res Clin Pract 2005; 69: 29-35. (Pubitemid 40813409)
25. Kim S, Keku TO, Martin C, et al. Circulating levels of inflammatory cytokines and risk of colorectal adenomas. Cancer Res 2008; 68: 323-8. (Pubitemid 351380135)
26. Wee CC, Mukamal KJ, Huang A, et al. Obesity, and C-reactive protein levels among White, Black, and Hispanic US adults. Obesity 2008; 16: 875-80. (Pubitemid 351465646)
27. Frezza EE, Wachtel MS, Chiriva-Internati M,. Influence of obesity on the risk of developing colon cancer. Gut 2006; 55: 285-91. (Pubitemid 43117290)
28. NHANES-III. U.S. Department of Health and Human Services (DHHS) National Center for Statistics; Third National Health and Nutrition Examination Survey, 1988-1994. Centers for Disease Control and Prevention, 1996.
29. Gunter EW, Lewis BG, Koncikowski SM,. Laboratory procedures used for the Third National Health and Nutrition Examination Survey (NHANES III), 1988-1994. National Center for Environmental Health, Centers for Disease Control and Prevention, and National Center for Health Statistics, 1996. http://www.cdc.gov/nchs/data/nhanes/nhanes3/cdrom/nchs/./labman.pdf.
30. Visser M, Bouter LM, McQuillan GM, et al. Elevated C-reactive protein levels in overweight and obese adults. JAMA 1999; 282: 2131-5.
31. NHANES-III. Linked mortality file: detailed notes for selected variables. National Center for Health Statistics, 2006.
32. NHLBI. Clinical guidelines on the identification, evaluation, and treatment of overweight and obesity in adults-the evidence report. National Heart Lung and Blood Institute, NIH Publication 98-4083, 1998. http://www.ncbi.nlm.nih.gov/books/NBK2003/.
33. S.A.S. Institute. SAS. Ver. 9.2, phase 1. Cary, NC: S.A.S. Institute Inc., 2008.
34. Ridker PM, Rifai N, Clearfield M, et al.; Air Force/Texas Coronary Atherosclerosis Prevention Study I. Measurement of C-reactive protein for the targeting of statin therapy in the primary prevention of acute coronary events. N Engl J Med 2001; 344: 1959-65. (Pubitemid 32568149)
35. Ridker PM, Cannon CP, Morrow D, et al.; Pravastatin or Atorvastatin E, Infection Therapy-Thrombolysis in Myocardial Infarction I. C-reactive protein levels and outcomes after statin therapy. N Engl J Med 2005; 352: 20-8.
36. Kones R,. The Jupiter study, CRP screening, and aggressive statin therapy-implications for the primary prevention of cardiovascular disease. Ther Adv Cardiovasc Dis 2009; 3: 309-15.
37. Siegel D, Lopez J, Meier J,. Use of cholesterol-lowering medications in the United States from 1991 to 1997. Am J Med 2000; 108: 496-9. (Pubitemid 30214202)
38. Kit BK, Ogden CL, Flegal KM,. Prescription medication use among normal weight, overweight, and obese adults, United States, 2005-2008. Ann Epidemiol 2012; 22: 112-19.
39. Gregg EW, Cheng YJ, Cadwell BL, et al. Secular trends in cardiovascular disease risk factors according to body mass index in US adults. JAMA 2005; 293: 1868-74. (Pubitemid 40548183)
40. Elwood PC, Gallagher AM, Duthie GG, et al. Aspirin, salicylates, and cancer. Lancet 2009; 373: 1301-9.
41. Liao X, Lochhead P, Nishihara R, et al. Aspirin use, tumor PIK3CA mutation, and colorectal-cancer survival. N Engl J Med 2012; 367: 1596-606.
42. Allin KH, Nordestgaard BG,. Elevated C-reactive protein in the diagnosis, prognosis, and cause of cancer. Crit Rev Clin Lab Sci 2011; 48: 155-70.
43. Vermeire S, Van Assche G, Rutgeerts P,. C-reactive protein as a marker for inflammatory bowel disease. Inflamm Bowel Dis 2004; 10: 661-5. (Pubitemid 39276479)
44. Tursi A,. Biomarkers in diverticular diseases of the colon. Dig Dis 2012; 30: 12-18.
45. Hisamatsu T, Okamoto S, Hashimoto M, et al. Novel, objective, multivariate biomarkers composed of plasma amino acid profiles for the diagnosis and assessment of inflammatory bowel disease. PloS One 2012; 7: e31131.
46. Grivennikov S, Karin E, Terzic J, et al. IL-6 and Stat3 are required for survival of intestinal epithelial cells and development of colitis-associated cancer. Cancer Cell 2009; 15: 103-13.
47. Atreya R, Neurath MF,. Involvement of IL-6 in the pathogenesis of inflammatory bowel disease and colon cancer. Clin Rev Allergy Immunol 2005; 28: 187-96.
48. Moscandrew ME, Loftus EV, Jr., Diagnostic advances in inflammatory bowel disease (imaging and laboratory). Curr Gastroenterol Rep 2009; 11: 488-95.
49. Calabro P, Chang DW, Willerson JT, et al. Release of C-reactive protein in response to inflammatory cytokines by human adipocytes: linking obesity to vascular inflammation. J Am Coll Cardiol 2005; 46: 1112-13. (Pubitemid 41316523)
50. Peyrin-Biroulet L, Gonzalez F, Dubuquoy L, et al. Mesenteric fat as a source of C reactive protein and as a target for bacterial translocation in Crohn's disease. Gut 2012; 61: 78-85.